NGM Biopharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of NGM Biopharmaceuticals generated cash of -$132,202,000, which is more than the previous year. Cash used in financing activities reached the amount of $1,775,000 last year. Net change in cash is therefore -$14,641,000.
Cash Flow
| 2016 | 1.26M | -64.70M | 231K |
|---|---|---|---|
| 2017 | -17.41M | -2.79M | 339K |
| 2018 | -7.59M | 38.72M | 198K |
| 2019 | -41.17M | 48.72M | 180.75M |
| 2020 | -83.49M | -50.99M | 35.53M |
| 2021 | -73.22M | -71.65M | 149.65M |
| 2022 | -144.43M | 14.32M | 54.23M |
| 2023 | -132.20M | 114.28M | 1.77M |
NGM Cash Flow Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 73.45M | 153.29M | 148.51M | 247.47M | 59.17M | 27.84M | 45.46M | 108.67M |
Operating activities | ||||||||
Net income | -142.37M | -162.66M | -120.33M | -102.48M | -42.79M | -493K | -14.15M | -6.92M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 2.22M | 4.03M | 6.08M | 6.55M | 7.60M | 7.22M | 6.44M | 3.53M |
Stock-based compensation expense | 28.71M | 32.38M | 26.24M | 15.65M | 12.98M | 9.96M | 7.71M | 6.01M |
| Deferred income tax benefit | 28.71M | 32.38M | 26.24M | 15.65M | 12.98M | 9.96M | 7.71M | 6.01M |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 7.52M | -2.63M | -3.11M | 4.87M | -1.53M | 0 | 0 | 0 |
Inventories | 0 | 2.63M | 3.11M | -4.87M | 1.53M | 0 | 0 | 0 |
Accounts payable | -4.97M | 3.20M | -4.41M | 910K | 3.64M | 3.48M | -4.23M | 2.75M |
Cash generated by operating activities | -132.20M | -144.43M | -73.22M | -83.49M | -41.17M | -7.59M | -17.41M | 1.26M |
Investing activities | ||||||||
Purchases Of Investments | -105.43M | -272.85M | -293.46M | -177.65M | -134.30M | -133.60M | -217.29M | -132.60M |
Investments In Property Plant And Equipment | -1.25M | -1.85M | -1.68M | -1.87M | -3.48M | -5.84M | -6.42M | -24.80M |
Acquisitions Net | 0 | -16.18M | 69.96M | 49.11M | -52.21M | 0 | 0 | 0 |
Cash generated by investing activities | 114.28M | 14.32M | -71.65M | -50.99M | 48.72M | 38.72M | -2.79M | -64.70M |
Financing activities | ||||||||
Common Stock Issued | 1.77M | 2.98M | 0 | 0 | 0 | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | -185K | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 1.77M | 54.23M | 149.65M | 35.53M | 180.75M | 198K | 339K | 231K |
Net Change In Cash | -14.64M | -75.88M | 4.77M | -98.95M | 188.3M | 31.33M | -19.87M | -63.20M |
Cash at end of period | 58.81M | 77.41M | 153.29M | 148.51M | 247.47M | 59.17M | 25.59M | 45.46M |
| Data source | Data source | Data source | Data source | Data source |